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Abstract Growing investments in health research by
governments and charitable organizations have fueled an
increase in collaborative research projects between inves-
tigators from afﬂuent and developing countries. Current
international guidelines are silent on common intra-con-
sortium data-sharing issues that arise in the context of such
collaborations. A lack of guidance on intra-consortium data
sharing threatens to undermine the success of crucial
research ventures. In this work we outline some of the
practical problems commonly faced by investigators
working in multi-institutional, international genomic col-
laborations and offer recommendations on these issues. A
data sharing policy should be prospectively negotiated and
concluded between collaborators as early as possible.
Sponsors of research, including those from developing
countries, should issue detailed guidance on the above and
related issues as doing so will facilitate research and cat-
alyze scientiﬁc progress.
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Introduction
Growing investments in health research by both govern-
ments and charitable organisations have fuelled an increase
in collaborative research projects between investigators
from afﬂuent and developing countries. Data sharing—
deﬁned as ‘‘the voluntary provision of information from
one individual or institution to another for purposes of
legitimate scientiﬁc research’’ (Hogue 1991)—can be
challenging in multi-institutional international genomic
collaborative ventures, particularly as investigators have
different expectations of their respective stakes in research
outcomes, and hail from different institutional and cul-
tural ideologies. Current international guidelines are silent
on common intra-consortium data-sharing issues. This
knowledge gap is fuelling uncertainty and threatens to
undermine the success of crucial research endeavors. In
this work we outline some of the practical intra-consortium
problems commonly faced by investigators working in
multi-institutional, international genomic collaborations
and offer recommendations on these issues.
Drafting and sharing: involve and invest
in developing world collaborators
Sponsors and principal investigators of international col-
laborations, such as the Centre for HIV/AIDS Vaccine
Immunology (CHAVI) and Grand Challenges in Global
Health (GCGH) Initiative, typically hail from afﬂuent
countries. These parties usually assume the responsibility
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ments. Intellectual Property (IP) regulatory and guidance
frameworks typically have a European or North American
basis. Moreover, there is often no or poor intellectual
property expertise available to consortium partners from
developing countries. Accordingly, data sharing or con-
sortium agreements drafted by PIs or sponsors from afﬂu-
ent countries are sometimes perceived by consortium
partners in developing countries as being biased in favour
of the interests of their consortium partners from the
developed world. PIs from afﬂuent countries should
accordingly ensure that their colleagues from the devel-
oping world are prospectively involved in the drafting of
consortium or data-sharing agreements. Such an approach
could see data access and research output issues explicitly
and meaningfully governed. Such an agreement should
describe the management of intellectual property rights
related to the proposed project, including plans for sharing
data, information, and materials resulting from the award.
The policy must also clearly govern the timing and means
of data release, and any constraints on release. (http://www.
ipm.ucdavis.edu/PD/pdrfp_attachb.html). We recommend
that local communities have a say in the management and
sharing of data relating to them.
However, involving developing world collaborators in
the drafting of a data sharing agreement will be meaning-
less if they are unable to access or interpret data. For
example, while consortium or data sharing agreements
typically specify database access rules (all consortium
partners usually have access to a common consortium
database) and research output rules (authorship sequence in
consortium publications is usually determined by the
respective contributions of consortium partners), partners
from developing countries often lack the resources to
access the pooled data, or the experience and conﬁdence to
equally contribute to research output based thereon. This
places the better-resourced and experienced collaborators
from afﬂuent countries at a distinct advantage in regard to
exploiting the common database and authoring publica-
tions based thereon. As such, developing world partners are
sometimes absent from consortium research outputs or
relegated to junior co-authorship status in such works.
In its 2002 statement on human genomic databases the
Hugo Ethics Committee declared that there is a scientiﬁc
responsibility to ensure the professional competence of
researchers working with data, as well as the quality and
accuracy of the data. (http://www.hugo-international.org/
PDFs/Statement%20on%20Human%20Genomic%20Data
bases%202002.pdf). Based on this guiding principle
principal investigators and partners from afﬂuent coun-
tries have a moral responsibility to build the capacity of
their developing world colleagues to enable them to
competently undertake the research in question and to
contribute to consortium-wide research outputs. This
may necessitate sponsors and/or principal investigators
investing in the infrastructure of their developing world
colleagues, for example, in compatible computer software
and broadband Internet access to enable developing world
partners to access consortium databases. Moreover, where
needed, collaborators from developed countries should
train their developing world partners to ensure they have
necessary expertise to exploit the research opportunities
in the consortium database.
Who owns data derived from consortia-wide efforts?
In privately funded research initiatives (to which interna-
tional agreements such as the Bermuda Accord, (http://
www.ornl.gov/sci/techresources/Human_Genome/research/
bermuda.shtml#2) or similar guidelines apply) and in
instances where recommended IP-related clauses in a data
sharing or consortium agreement (http://www.jisclegal.ac.uk/
publications/IRPConsortia.htm) are absent, it can be argued
that data derived from consortia-wide efforts are the pro-
prietary interests of the consortium as a whole. As such, the
authorization to publish such data ought to be obtained
from a specially constituted publication and data access
committee comprising consortium members and/or inde-
pendent experts from developed and developing countries.
The decisions of such a committee should be binding.
Who has the right to publish consortium-derived data
ﬁrst?
In multi-institutional collaborations, particularly those
focusing on genomic variance, partners usually share their
site-sourced data/specimens with all members of the con-
sortium. These are analyzed by designated consortium
partners—in many instances, the principal investigator—and
ultimately form part of a common database accessible to all
consortium members. Site-speciﬁc genotypic results are usu-
allyalsomadeavailabletothecontributingpartnerwhenthese
become available. Data sharing guidelines of major sponsors
(NIH: http://grants1.nih.gov/grants/policy/data_sharing/index.
htm; Wellcome Trust: http://www.wellcome.ac.uk/print/WTX
035045_print.html; MRC, UK: http://www.mrc.ac.uk/Policy
Guidance/EthicsAndGovernance/DataSharing/PolicyonData
SharingandPreservation/index.htm; National Academies of
Sciences,USA:http://books.nap.edu/catalog.php?record_id=
10613#toc) are silent on whether parties are entitled to
publish an analysis of their results using clinical and demo-
graphic data at their disposal, in combination with consor-
tium-derived but site-speciﬁc genotypic data, prior to a
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analysis of the cumulative data.
MalariaGEN investigators—who are faced with such a
dilemma—recommend that a data-sharing policy begin by
demarcating resources—samples, data, and infrastruc-
ture—that will be shared across the consortium and those
that remain in the domain of individual investigators.
(Chokshi et al. 2006) They stress that a clear distinction be
made between ‘‘consortium experiments’’ (where data is
analyzed across the whole consortium) and ‘‘investigator-
initiated analyses’’ (where individual collaborator groups
utilize the data they have collected together with any data
that may have been generated on those samples in the
consortium experiments. We endorse Malaria-Gen’s rec-
ommendations on how these resources should be managed.
From the outset of its existence, MalariaGEN established
an in-house ethics team to address data sharing and other
consortium-related issues. This is a model that other con-
sortiums may want to consider adopting.
If a consortium is not governed by a prospectively
negotiated data sharing policy that governs data release,
collaborating partners should weigh the costs and beneﬁts
of publishing the site-speciﬁc genotypic data before a
group publication. If the publication of the site-speciﬁc
data threatens the intellectual property interests of other
consortium partners or the consortium as a whole, the
consortium partner seeking to publish its work ahead of a
consortium-wide work ought to desist from doing so. On
the other hand, consortium-wide works are dependent on
consensus being reached between consortium partners on
key ﬁndings, are sometimes subject to authorship sequence
disputes, and, as such, can take long to reach the public
domain. Such instances could unnecessarily delay the
reporting of important site-speciﬁc genetic data by indi-
vidual partners and could be detrimental to scientiﬁc
advances in that ﬁeld. This could negatively impact on
those who could most beneﬁt from that information. In the
event of the latter, a strong argument can be made for the
site-speciﬁc data of collaborating partners to be published
ahead of a consortium-wide work. In the event of a dispute
arising between consortium partners on data release, the
dispute should be referred to the aforementioned proposed
publication and data access committee. In such instances,
the onus of proving the merits of a particular data release
strategy should rest with its proponents.
Are consortium partners entitled to share their data
derived from the consortium with non-consortium
members?
Unless a consortium is bound by a data sharing agreement
the sharing of consortium data with non-consortium
members by individual consortium partners could under-
mine consortium-wide research outputs and have intellec-
tual property implications for those concerned. In such
instances, data derived from consortium collaborations
ought to be considered the proprietary interests of the
consortium as a whole. CHAVI’s service contract, which is
entered into by all CHAVI members and collaborators,
stipulates that CHAVI collaborators and members ‘‘may at
their sole discretion share their own respective other data
that has not been published or otherwise publicly dis-
closed…’’ with non-CHAVI scientists subject to authori-
zation being obtained from the non-proﬁt entity [such as a
university] that generated the proprietary material and a
conﬁdential disclosure agreement being entered into
between the relevant parties (CHAVI: amended and
restated research consortium agreement, paragraph 8.1.4).
In the absence of being bound by a prospectively negoti-
ated data-sharing or consortium agreement governing this
issue, genetic data derived from consortium-wide endeav-
ors ought not to be shared with non-consortium members
unless authorization has been obtained from the afore-
mentioned publication and data sharing committee. Mem-
bers of this committee who have conﬂicts of interests in a
matter at hand ought to recuse themselves.
Conclusion
A data sharing policy should be prospectively negotiated
and concluded between collaborators as early as possible.
We urge sponsors of research, including those from devel-
oping countries, to issue detailed guidance on the above and
related issues as doing so will facilitate research and cata-
lyze scientiﬁc progress. We also invite others to contribute
to this important discourse by sharing their perspectives on
data sharing and research output governance.
Summary
Good practice recommendations on data sharing
1. Consortium data sharing and intellectual property
agreements should be negotiated and concluded among
collaborators as early as possible. Research collabo-
rators from the developing world should be prospec-
tively involved in the drafting of such documents to
ensure that data access and research output issues are
explicitly and meaningfully governed.
2. A data sharing policy should describe the management
of intellectual property rights related to the proposed
project, including plans for sharing data, information,
and materials resulting from the award. It should
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ture—that will be shared across the consortium and
those that remain in the domain of individual inves-
tigators. The policy must be speciﬁc about the nature
of the data to be shared, the timing and means of
release, and any constraints on release.
3. Local communities should have a say in the manage-
ment and sharing of site-speciﬁc data relating to them.
4. Principal investigators and partners from afﬂuent
countries have a moral responsibility to build the
capacity of their developing world colleagues to enable
them to competently undertake the research in question
and contribute to consortium-wide research outputs.
5. In privately funded research initiatives which are not
governed by international guidelines, and in instances
whererecommendedIP-relatedclausesinadatasharing
or consortium agreement are absent, data derived from
consortia-wide efforts should be considered the pro-
prietary interests of the consortium as a whole.
6. Authorization to publish data derived from consor-
tium-wide efforts ought to be obtained from a specially
constituted publication and data access committee
comprising consortium members and/or independent
experts from developed and developing countries.
7. If the publication of site-speciﬁc data threatens the
intellectual property interests of other consortium
partners or the consortium as a whole, the consortium
partner seeking to publish its work ahead of a
consortium-wide work ought to desist from doing so.
8. Where delays in the reporting of important site-speciﬁc
genetic data by individual partners could be detrimen-
tal to scientiﬁc advances in that ﬁeld and to those who
could most beneﬁt from that information, site-speciﬁc
data of collaborating partners should to be published
ahead of a consortium-wide work, subject to disputes
related to such dissemination being settled by a
consortium publication and data access committee.
9. Data derived from consortium-wide endeavors ought
not to be shared with non-consortium members unless
authorization has been obtained from a publication and
data sharing committee.
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